| 101.57 0.03 (0.03%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 119.07 | 1-year : | 139.08 |
| Resists | First : | 101.94 | Second : | 119.07 |
| Pivot price | 101.48  |
|||
| Supports | First : | 101.09 |
Second : | 100.55 |
| MAs | MA(5) : | 101.66 |
MA(20) : | 101.41 |
| MA(100) : | 67.64 |
MA(250) : | 0 | |
| MACD | MACD : | 4.7  |
Signal : | 6 |
| %K %D | K(14,3) : | 61.6 |
D(3) : | 70.3 |
| RSI | RSI(14): 85 |
|||
| 52-week | High : | 101.94 | Low : | 38.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EXAS ] has closed below upper band by 41.3%. Bollinger Bands are 92.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 101.75 - 102.36 | 102.36 - 102.95 |
| Low: | 100.03 - 100.77 | 100.77 - 101.47 |
| Close: | 100.45 - 101.53 | 101.53 - 102.56 |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Wed, 24 Dec 2025
Exact Sciences Corporation (NASDAQ:EXAS) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Sun, 07 Dec 2025
Norges Bank Takes Position in Exact Sciences Corporation $EXAS - MarketBeat
Thu, 20 Nov 2025
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday - Investopedia
Thu, 20 Nov 2025
Abbott To Complete $21B M&A Deal For Exact Sciences - What Investors Should Know - Seeking Alpha
Thu, 20 Nov 2025
EXAS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Exact Sciences Corporation is Fair to Shareholders - Business Wire
Thu, 20 Nov 2025
Madison’s Exact Sciences will be acquired by Abbott health care company - WPR
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 190 (M) |
| Shares Float | 188 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 95.3 (%) |
| Shares Short | 5,100 (K) |
| Shares Short P.Month | 7,940 (K) |
| EPS | -5.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.19 |
| Profit Margin | -32.1 % |
| Operating Margin | -0.2 % |
| Return on Assets (ttm) | -1.1 % |
| Return on Equity (ttm) | -34.6 % |
| Qtrly Rev. Growth | 20.1 % |
| Gross Profit (p.s.) | 11.27 |
| Sales Per Share | 16.23 |
| EBITDA (p.s.) | 0.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 387 (M) |
| Levered Free Cash Flow | 234 (M) |
| PE Ratio | -18.99 |
| PEG Ratio | 0 |
| Price to Book value | 7.69 |
| Price to Sales | 6.25 |
| Price to Cash Flow | 49.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|